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ABSTRACT 
A novel method for in situ preparation of injectable biodegradable 
microspheres from the copolymer poly(lactide-co-glycolide) (PLGA) without 
incorporating unacceptable organic solvents is described. The delivery system is 
a dispersion of PLGA microglobules ("premicrospheres" or "embryonic 
microspheres") in an acceptable vehicle mixture (continuous phase) and whose 
integrity is maintained by use of appropriate stabilizers. A solution of PLGA. 
triacetin, drug, PEG 400, and Tween 80 (Oil Phase 1) are added dropwise with 
continuous homogenization to miglyol 812-Span 80 solution (Oil Phase 2), 
thereby inducing phase separation (coacervation) of PLGA and forming PLGA 
microglobules (containing the drug) dispersed in the continuous phase. This 
novel drug delivery system (NDDS) is a dispersion and has a viscous consistency 
but is sufficiently syringeable. When injected, it comes in contact with water 
from aqueous buffer or physiological fluid and as a result, the microglobules 
harden to form solid matrix type microparticles entrapping the drug (in situ 
formed microspheres) . The drug is then released from these microspheres in a 
controlled fashion. 
This novel microencapsulation process overcomes some of the 
disadvantages associated with the existing methods by: (i) excluding the use of 
unacceptable organic solvents and using acceptable vehicle mixture instead to 
prepare biodegradable PLGA microspheres, (ii) forming drug containing PLGA 
microglobules ("premicrospheres" or "embryonic microspheres") which could be 
considered as precursors to the final microsphere product; these on coming in 
contact with water harden to form discreet PLGAmicrospheres which 
subsequently exhibit non-variable, predictable, and controlled drug release profile, 
and (iii) precluding the need for reconstitution of the PLGA microspheres before 
their administration. 
The composition, rationale, and optimization of the NDDS is described 
here. The characteristics of this NDDS were affected by various formulation 
( 
varibles such as: (i) the PLGA concentration and type, (ii) the substitution of the 
continuous phase by a fresh Oil Phase 2, (iii) the concentration of PEG 400 and 
the encapsulated drug, (iv) the addition of an hydrophilic excipient (mannitol), 
and (v) the types of encapsulated drugs and the vehicles added to the system. The 
characteristics of the NDDS were reproducible and were not affected by a 15 
days/4° C storage condition. Also, the formulation, process, and the storage ( i 5 
days/4° C) conditions did not adversely affect the physical stability of the 
encapsulated proteins. 
Besides producing injectable in situ formed microspheres, this novel 
microencapsulation process can be modified to yield injectable in situ formed 
implant or isolated microspheres. Thus this novel microencapsulation process is 
versatile and it can produce various drug loaded injectable biodegradable PLGA 
devices having different characteristics. 
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PREFACE 
This dissertation has been written in the Manuscript Format as per the 
guidelines issued by The Graduate School at the University of Rhode Island. This 
option was most suitable to present my results in several sections. 
Section I constitutes the Objectives and Introduction of this dissertation. 
The manuscripts in Section II are the core of this dissertation. Section III consists 
of the Conclusion and Final Remarks of this dissertation. 
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OBJECTIVES 
The main intention of this research project were to achieve controlled drug 
delivery of micromolecules and macromolecules, such as proteins, from a novel 
injectable biodegradable poly(lactide-co-glycolide) (PLGA) microsphere system. 
This system would overcome some of the disadvantages associated with the 
traditional methods for controlled drug delivery. On injection, the system would 
come in contact with water from aqueous buffer or physiological fluid and as a 
result, form solid matrix type microparticles entrapping the drug (in situ formed 
microspheres); the drug would be released from these microspheres in a 
controlled fashion. 
The specific objectives of this research project were as follows: 
(1) To develop a novel method for controlled delivery of drugs from an in situ 
forming biodegradable PLGA microsphere system. 
(2) To evaluate the effects of various formulation variables on the 
characteristics of this system. 
(3) To determine the effects of formulation, process and storage conditions on 
the reproducibility and stability of this system as well as the stability of 
the encapsulated proteins. 
(4) To modify this novel microencapsualtion process, to produce in situ 
formed implant or isolated microspheres and also compare the 
characteristics of the three biodegradable devices: in situ formed implant 
v/s in situ formed microsphres v/s isolated microspheres. 
2 
f 
INTRODUCTION 
To avoid inconvenient surgical insertion of large implants. injectable 
biodegradable and biocompatible polymeric particles (microparticles and 
nanoparticles) could be employed for parenteral controlled-release dosage forms . 
Microparticles of size less than 250 µm, ideally less than 125 ~Lrn are suitable for 
this purpose. Biodegradable polymers are natural or synthetic in origin and are 
decomposed in vivo, either enzymatically or non-enzymatically to produce 
biocompatible, toxicologically safe by-products which are further eliminated by 
normal metabolic pathways. Drugs formulated in polymeric devices are released 
either by diffusion through the polymer barrier, or by erosion of the polymer 
material, or by a combination of both diffusion and erosion mechanisms. The 
polymers selected for the parenteral administration must meet several 
requirements like biocompatibility, drug compatibility, suitable biodegradation 
kinetics and mechanical properties, and ease of processing. 
Although a wide variety of natural and synthetic biodegradable polymers 
have been investigated for drug targeting or prolonged drug release, only a few of 
them are actually biocompatible. Natural biodegradable polymers like bovine 
serum albumin (BSA), human serum albumin (HSA), collagen, gelatin, and 
hemoglobin have been studied for drug delivery. The use of these natural 
polymers is limited due to their higher costs and questionable purity. 
In the past two decades synthetic biodegradable polymers have been 
increasingly used to deliver drugs, since they are free from most of the problems 
associated with natural polymers. Poly(amides), poly( amino acids), poly(alkyl-cx.-
cyano acrylates), poly(esters), poly(orthoesters), poly(urethanes), and 
poly(acrylamides) have been used to prepare polymeric devices to deliver drugs. 
Amongst them, the thermoplastic aliphatic poly( esters) like poly(lactide) (PLA). 
poly(glycolide) (PGA), and especially the copolymer of lactide and glycolide 
referred to as poly(lactide-co-glycolide) (PLGA) have generated immense interest 
due to their excellent biocompatibility and biodegradability. Also PLGA has been 
3 
approved by the U.S. FDA for a number of clinical applications including surgical 
sutures and as controlled-release microspheres. PLGA is shown to be 
biocompatible and degrades to toxicologically acceptable lactic and glycolic acids 
that are eventually eliminated from the body. Release of drugs from PLGA 
microspheres occurs by two mechanisms: (i) diffusion of the drug through a 
tortuous, water-filled path in the polymer matrix and (ii) matrix bioerosion (bulk 
hydrolytic degradation) after undergoing sufficient hydration. The actual release 
is a combination of both the processes. 
There is a particular interest in controlled delivery of macromolecules like 
peptides and proteins through PLGA microspheres. Although a wide variety of 
pharmacologically useful peptide and protein based drugs have been recently 
developed by genetic engineering, their therapeutic use is restricted due to certain 
disadvantages: (i) on oral consumption they are subject to attack by the acidic and 
enzymatic environment in the stomach and the enzymes from the brush border 
membrane of the intestine, (ii) their high molecular weight and size impede their 
effective transport across the gastrointestinal membranes, and (iii) they have a 
short biological half-life and on injection they are quickly metabolized and 
eliminated. To achieve sustained blood levels of these drugs, minimize their 
denaturation or degradation, and to extend their biological half-life, their delivery 
by encapsulation in PLGA microspheres has become an interesting approach. 
The literature on PLGA microspheres is full of different techniques 
describing their manufacture, where the microspheres are produced in a free-
flowing, powder form. Some of the methods reported are : (i) single/double 
emulsification followed by solvent removal by evaporation or extraction, (ii) 
phase separation ( coacervation), and (iii) spray-drying. Most of these 
manufacturing processes suffer from drawbacks such as: (i) the microspheres need 
to be reconstituted (suspended) in an aqueous media, before they could be injected 
in the body, (ii) the hazards and environmental concern associated with the use of 
organic solvents like methylene chloride for the solubilization of PLGA polymer, 
and (iii) residual organic solvents remaining in the final microsphere product. 
4 
Shah et al and researchers from Atrix Laboratories, Inc. (Fort Collins. CO) 
have described a novel implant system which is parenterally administered as a 
liquid and subsequently solidifies into a gel matrix (implant) in situ, from which 
the drug is released in a controlled manner. Although this implant system 
precludes the need for any surgery for its administration, it has a number of 
disadvantages: (i) the safety of solvents like N-methyl-2-pyrrolidone. used to 
formulate these systems is questionable and not well documented, (ii) the 
injection of these liquid implant systems and their subsequent solidification 
produce non-uniform matrix implants having variable consistency and geometry. 
and (iii) due to formation of matrix implants having inconsistent texture. shape 
and size, the drug release from them is variable and unpredictable. 
The present process of microsphere formation is based on the principle of 
coacervation. This method overcomes the problems faced by the above systems 
by forming a dispersion of PLGA micro globules ("premicrospheres" or 
"embryonic microspheres") in an acceptable vehicle mixture (continuous phase) 
and whose integrity is maintained by use of appropriate stabilizers. A solution of 
PLGA, triacetin, drug, PEG 400, and Tween 80 (Oil Phase 1) are added dropwise 
with continuous homogenization to miglyol 812-Span 80 solution (Oil Phase 2), 
thereby inducing phase separation ( coacervation) of PLGA and forming PLGA 
microglobules (containing the drug) dispersed in the continuous phase. This 
novel drug delivery system (NDDS) is a dispersion and has a viscous consistency, 
but is sufficiently syringeable. When injected, it comes in contact with water 
from aqueous buffer or physiological fluid and as a result, the microglobules 
harden to form solid matrix type microparticles entrapping the drug (in situ 
formed microspheres). The drug is then released from these microspheres in a 
controlled fashion. This novel microencapsulation method can be modified to 
produce other biodegradable PLGA devices exhibiting controlled drug delivery. 
5 
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SECTION II 
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MANUSCRIPT I 
CONTROLLED DRUG DELIVERY BY BIODEGRADABLE POL Y(ESTER) 
DEVICES: DIFFERENT PREPARATIVE APPROACHES 
7 
/ 
ABSTRACT 
There has been extensive research on drug delivery by biodegradable 
polymeric devices since bioresorbable surgical sutures entered the market two 
decades ago. Amongst the different classes of biodegradable polymers, the 
thermoplastic aliphatic poly(esters) like poly(lactide) (PLA), poly(glycolide) 
(PGA), and especially the copolymer of lactide and glycolide referred to as 
poly(lactide-co-glycolide) (PLGA) have generated interest due to their excellent 
biocompatibility, biodegradability, and mechanical strength. Also, they are easy 
to formulate into various devices for carrying a variety of drug classes such as 
vaccines, peptides, proteins, and micromolecules; most importantly they have 
been approved by the Food and Drug Administration (FDA) for drug delivery. 
This review presents different techniques of preparation of various drug 
loaded PLGA devices, with special emphasis on preparing microparticles. Certain 
issues about other related biodegradable polyesters are discussed. 
8 
INTRODUCTION 
A controlled drug action may be achieved by either chemically modifying 
the drug moiety (e.g. prodrug) or by formulating it in a specific way to control its 
release. Oral controlled-release dosage forms, depending upon the drug 
employed, can provide efficacy for about 24 hr. (1). Oral dosage forms may not 
be feasible in cases where the drug undergoes extensive degradation in the 
gastrointestinal tract, exhibits significant first-pass effect, or is poorly absorbed. 
Of serious concern are the problems associated with the oral administration of 
peptide/protein drugs which are subject to attack by the acidic and enzymatic 
environment in the stomach and the enzymes from the brush border membrane of 
the intestine. Also their high molecular weight and size impede their effective 
transportation across the gastrointestinal tract membranes. The main drawback of 
oral dosage forms are the short transit time of approximately twelve hours through 
the gastrointestinal tract (2). Further, if the drug is absorbed only through a 
specific area of the gastrointestinal tract, the duration of action could be less than 
twelve hours (2). 
If a drug cannot be administered orally due to any of the above reasons, a 
parenteral route of delivery is an alternative. One advantage that a parenteral 
controlled release dosage form has over oral controlled release dosage forms is 
patient compliance (2). Although an oral dosage form might have a good 
bioavailability, a long-acting parenteral dosage form that is safe and efficacious 
for days or weeks or months could be beneficial because it ensures that the patient 
is receiving medication. Also a parenteral controlled release dosage form is 
preferred over conventional parenteral dosage form for chronic treatment where 
routine multiple injections could be inconvenient and painful. Parenteral 
controlled release dosage forms are also effective in site-specific drug delivery. 
thereby improving its efficacy and reducing its toxicity. The main disadvantage 
of these dosage forms is that once administered, they cannot be easily removed 
(2). This could be a problem for the patient if a drug was no longer needed. or 
worse if it caused an undesirable reaction. 
9 
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To avoid inconvenient surgical insertion of large implants, injectable 
biodegradable and biocompatible polymeric particles (microspheres, 
microcapsules, nanocapsules, nanospheres) could be employed for parenteral 
controlled-release dosage forms ( 1 ). Microparticles of size less than 250 ~Lm, 
ideally less than 125 µmare suitable for this purpose (2). Biodegradable 
polymers are natural or synthetic in origin and are decomposed in vivo, either 
enzymatically or non-enzymatically to produce biocompatible, toxicologically 
safe by-products which are further eliminated by normal metabolic pathways (3). 
Drugs formulated in polymeric devices are released either by diffusion through 
the polymer barrier, or by erosion of the polymer material, or by a combination of 
both diffusion and erosion mechanisms (4). The polymers selected for the 
parenteral administration must meet several requirements like biocompatibility, 
drug compatibility, suitable biodegradation kinetics and mechanical properties, 
and ease of processing ( 4, 5). 
Although a wide variety of natural and synthetic biodegradable polymers 
have been investigated for drug targeting or prolonged drug release, only a few of 
them are actually biocompatible. Natural biodegradable polymers like bovine 
serum albumin (BSA), human serum albumin (HSA), collagen, gelatin, and 
hemoglobin have been studied for drug delivery (1 ). The use of these natural 
polymers is limited due to their higher costs and questionable purity ( 1 ). 
In the past two decades synthetic biodegradable polymers have been 
increasingly used to deliver drugs, since they are free from most of the problems 
associated with natural polymers (1-8). Poly(amides), poly( amino acids), 
poly(alkyl-a-cyano acrylates), poly(esters), poly(orthoesters), poly(urethanes). 
and poly(acrylamides) have been used to prepare polymeric devices to deliver 
drugs (1-7). Amongst them, the thermoplastic aliphatic poly(esters) like 
poly(lactide) (PLA), poly(glycolide) (PGA), and especially the copolymer of 
lactide a·nd glycolide referred to as poly(lactide-co-glycolide) (PLGA) have 
generated immense interest due to their excellent biocompatibility and 
IO 
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biodegradability (1-17). Also they are easy to formulate into drug carrying 
devices and have been approved by the FDA for drug delivery use ( 13-17). 
This review provides a comprehensive outlook on different techniques of 
preparation of various drug loaded PLGA devices, with special emphasis on 
preparing microparticles. Certain issues about other related biodegradable 
polyesters like PLA and PGA have been discussed as well. 
HISTORICAL DEVELOPMENT OF DRUG DELIVERY USING PLGA 
The discovery and the synthetic work on low molecular weight oligomeric 
forms of lactide and/or glycolide polymers was first carried out several decades 
back (3, 5). The methods to synthesize high molecular weights of these polymers 
were first reported by Lowe (3). 
During the late 1960s and early 1970s a number of groups had published 
pioneering work on the the utility of these polymers to make sutures/fibers (2, 3, 
5, 12). These fibers had several advantages such as good mechanical properties. 
low immunogenicity and toxicity, excellent biocompatibility, and predictable 
biodegradation kinetics (2, 3, 5, 12). The wide acceptance of the lactide/glycolide 
polymers as suture materials, made them an attractive candidate for biomedical 
applications like ligament reconstruction, tracheal replacement, ventral 
hemiorrhaphy, surgical dressings, vascular grafts, nerve, dental, and fracture 
repairs (3, 5, 9). 
The biodegradation, biocompatibility, and tissue reaction of PLA and 
PLGA have been extensively investigated and well documented by many 
researchers (5, 14). The first work on parenteral controlled release of drugs using 
PLA was reported by Boswell, Yalies, Sinclair, Wise, and Beck (3, 5) . Since then 
an ocean of literature on drug delivery using PLA, and especially PLGA has been 
published. Various polymeric devices like microspheres, microcapsules, 
nanoparticles, pellets, implants, and films have been fabricated using these 
polymers for the delivery of a variety of drug classes. 
11 
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SYNTHESIS OF PLGA COPOLYMER 
Low molecular weight PLGA can be prepared by direct condensation 
(polyesterification) of lactic and/or glycolic acids (5, 12). Temperatures as high 
as 130-190° C are required for the condensation process and the water generated is 
removed by boiling, using vacuum, purging with nitrogen, or azeotropic 
distillation with an organic solvent (3, 12). An acid catalyst like antimony oxide 
increases the reaction rate if used at reaction temperatures below 120° C. but 
above this temperature water removal is the rate-limiting step (3, 12). This 
method yields PLGA having molecular weight of - l 0,000 ( 12). The low 
molecular weight PLGA has limited biomedical application, due to its poor 
mechanical strength and faster degradation (3). 
Intermediate and high molecular weight PLGA (-10,000-40,000) can be 
prepared by the ring-opening polymerization of the cyclic dimers (cyclic diester 
of lactic and/or glycolic acids) as the starting materials (3, 5, 12, 14). The 
advantage of this method is that no water removal/dehydration method is needed 
in the polymerization system (3). Also the cyclized monomer(s) and the linear 
form of the polymers produced can be readily purified (3). Compounds of lead. 
tin, cadmium, zinc, antimony, and titanium have been used as catalyst to initiate 
the polymerization process (12, 14). Acid catalyzed bulk polymerization (melt 
method) for two to six hours at around 175° C is generally employed for 
preparation of PLGA from lactide and glycolide monomers (3 ). The molecular 
weight of the resultant PLGA is determined by the concentration of the catalyst 
added (12). Monomer purity of99.9% or greater and monomer acidity of 0.05% 
or less are required with the starting lactide and glycolide materials (5). Also 
important are the low levels of humidity in the processing area (5). 
PHYSICAL, CHEMICAL, AND BIOLOGICAL PROPERTIES OF PLGA 
It is important to understand the physical, chemical, and biological 
properties of the polymer before formulating a controlled drug delivery device . 
The various properties of the polymer and the encapsulated drug directly 
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influence other factors like the selection of the microencapsulation process, drug 
release from the polymer device, etc. (1). 
PLA can exist as the optically active stereoregular polymer (L-PLA) and a 
optically inactive racemic polymer (D, L-PLA) (1 , 5, 9) . L-PLA is found to be 
semicrystalline in nature due to high regularity of its polymer chain while D, L-
PLA is an amorphous polymer because of irregularities in its polymer chain 
structure (3 , 9). Hence the use of D, L-PLA is preferred over L-PLA as it enables 
more homogeneous dispersion of the drug in the polymer matrix (9. 13 ). PGA is 
highly crystalline because it lacks the methyl side groups of the PLA (3, 9). 
Lactic acid is more hydrophobic than glycolic acid and hence lactide-rich PLGA 
copolymers are less hydrophilic, absorb less water, and subsequently degrade 
more slowly (1, 3, 13). 
The molecular weight and polydispersity index of the polymer are factors 
which affect the mechanical strength of the polymer and its ability to be 
formulated as a drug delivery device (3, 5, 12). Also these properties may control 
the polymer biodegradation rate and hydrolysis (3, 12). The commercially 
available PLGA polymers are usually char!lcterized in terms of intrinsic viscosity 
which is directly related to their molecular weights (3). 
The degree of crystallinity of the PLGA polymer directly influences its 
mechanical strength, swelling behavior, capacity to undergo hydrolysis, and 
subsequently its biodegradation rate (3) . The resultant crystallinity of the PLGA 
copolymer is dependent on the type and the molar ratio of the individual monomer 
components (lactide and glycolide) in the copolymer chain (1). PLGA polymers 
containing 50:50 ratio of lactic and glycolic acids are hydrolyzed much faster than 
those containing higher proportion of either of the two monomers (5, 12). PLGAs 
prepared from L-PLA and PGA are crystalline copolymers while those from 0, L-
PLA and PGA are amorphous in nature (3, 5). Gilding and Reed have pointed out 
that PLGAs containing less than 70 % glycolide are amorphous in nature ( 18). 
The degree of crystallinity and the melting point of the polymers are directly 
related to the molecular weight of the polymer (3, 5). 
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The glass transition temperature (Tg) of the PLGA copolymers are above 
the physiological temperature of 37° C and hence they are glassy in nature (3. 5). 
Thus they have a fairly rigid chain structure which gives them significant 
mechanical strength to be formulated as drug delivery devices (3. 5). Jamshidi et 
al. have reported that Tg of PLGAs decrease with decrease of lactide content in 
the copolymer composition and with decrease in their molecular weight ( 19). 
It is important for the PLGA polymers to have considerable mechanical 
strength since the drug delivery devices formulated using them are subjected to 
significant physical stress (3 , 5). Different factors like the molecular weight. 
copolymer composition (lactide/glycolide ratio), crystallinity, and geometric 
regularity of individual chains significantly affect the mechanical strength of the 
polymer (1 , 3, 5). 
In vitro and in vivo the PLGA copolymer undergoes degradation in an 
aqueous environment (hydrolytic degradation or biodegradation) through cleavage 
of its backbone ester linkages (1-3 , 5, 12, 13). The polymer chains undergo bulk 
degradation and the degradation occurs at uniform rate throughout the PLGA 
matrix (3, 13). Thies and Bissery have reported that the PLGA biodegradation 
occurs through random hydrolytic chain scissions of the swollen polymer (20). 
The carboxylic end groups present in the PLGA chains increase in number during 
the biodegradation process as the individual polymer chains are cleaved; these are 
known to catalyze the biodegradation process (3, 5). The biodegradation rate of 
the PLGA copolymers are dependent on the molar ratio of the lactic and glycolic 
acids in the polymer chain, molecular weight of the polymer, the degree of 
crystallinity, and the Tg of the polymer (3, 5, 13). A three phase mechanism for 
the PLGA biodegradation has been proposed (21 ): 
1. Random chain scission process. The molecular weight of the polymer 
decreases significantly, but no appreciable weight loss and no soluble monomer 
products formed. 
2. In the middle phase a decrease in molecular weight accompanied by rapid loss 
of mass and soluble oligomeric and monomer products are formed. 
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3. Soluble monomer products formed from soluble oligomeric fragments. This 
phase is that of complete polymer solubilization. 
The extent, if any, on the role of enzymes in the PLGA biodegradation is 
unclear (3, 5). Most of the literature indicates that the PLGA biodegradation does 
not involve any enzymatic activity and is purely through hydrolysis (3). 
However, some investigators have suggested an enzymatic role in PLGA 
breakdown based upon the difference in the in vitro and in vivo degradation rates 
(5). 
The PLGA polymer biodegrades into lactic and glycolic acids ( 1-3, 5, 12. 
13). Lactic acid enters the tricarboxylic acid cycle and is metabolized and 
subsequently eliminated from the body as carbon dioxide and water (1-3 , 5. 9). ln 
a study conducted using 14C-labeled PLA implant, it was concluded that lactic 
acid is eliminated through respiration as carbon dioxide (22). Glycolic acid is 
either excreted unchanged in the kidney or it enters the tricarboxylic acid cycle 
and is eventually eliminated as carbon dioxide and water (3). 
METHODS OF PREPARING VARIOUS PLGA DEVICES 
[1] MICROPARTICLES 
A number of microencapsulation techniques have been developed and 
reported to date. The choice of the technique depends on the nature of the 
polymer, the drug, the intended use, and the duration of the therapy (1 , 2, 4, 5, 
10). The microencapsulation method employed must include the following 
requirements (1, 2, 23): 
(i) The stability and biological activity of the drug should not be adversely 
affected during the encapsulation process or in the final microsphere product. 
(ii) The yield of the microspheres having the required size range (upto 250 
µm, ideally < 125 µm) and the drug encapsulation efficiency should be high. 
(iii) The microsphere quality and the drug release profile should be 
reproducible within specified limits. 
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(iv) The microspheres should be produced as a free flowing powder and should 
not exhibit aggregation or adherence. 
A. Solvent Evaporation and Solvent Extraction Process 
(1) Single emulsion process 
This is essentially an oil-in-water (o/w) emulsion process. The polymer is 
first dissolved in a water immiscible, volatile organic solvent; dichloromethane 
(DCM) most commonly used. The drug is then added to the polymer solution to 
produce a solution or dispersion of the drug particles (particle size of the drug 
added to be< 20 µm) (4). This polymer-solvent-drug solution/dispersion is then 
emulsified (with appropriate stirring and temperature conditions) in a larger 
volume of water in presence of an emulsifier (such as poly (vinyl alcohol) (PY A)) 
to yield an o/w emulsion. The emulsion is then subjected to solvent removal by 
either evaporation or extraction process to harden the oil droplets (I 0). In the 
former case the emulsion is maintained at reduced pressure or at atmospheric 
pressure and the stirring rate reduced to enable the volatile solvent to evaporate ( 4, 
10). In the latter case the emulsion is transferred to a large quantity of water (with 
or without surfactant) or other quench medium, into which the solvent associated 
with the oil droplets diffuses ( 4, 10). The solid microspheres so obtained are then 
washed and collected by filtration, sieving, or centrifugation ( 4 ). These are then 
dried under appropriate conditions or are lyophilized to give the final free flowing 
injectable microsphere product. 
It should be noted that the solvent evaporation process in a way is similar 
to the extraction method, in the sense that the solvent must first diffuse out into 
the external aqueous dispersion medium before it could be removed from the 
system by evaporation ( 4, 10). The rate of solvent removal by the extraction 
method depends on the temperature of quench water or other medium, ratio of 
emulsion volume to quench water/medium volume and the solubility 
characteristics of the polymer, the solvent, and the dispersion medium. The rate 
of solvent removal by evaporation method strongly influences the characteristics 
of the final microspheres and it depends on the temperature. pressure, and the 
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solubility parameters of the polymer, the solvent, and the dispersion medium (I 0). 
Very rapid solvent evaporation may cause local explosion inside the droplets and 
lead to formation of porous structures on the microsphere surface (I 0). Solvent 
removal by extraction method is more faster (generally< 30 min) than the 
evaporation process and hence the microspheres made by the former method are 
more porous in comparison to those made from the latter method under similar 
conditions (10). 
The biggest drawback of the o/w emulsification method is poor 
encapsulation efficiencies of moderately water soluble and water soluble drugs ( 1, 
4, 10). The drug would diffuse out or partition from the dispersed oil phase into 
the aqueous continuous phase and microcrystalline fragments of the hydrophilic 
drugs get deposited on the microsphere surface and dispersed in the PLGA matrix 
(24, 25). This would result in poor trapping of the hydrophilic drug such as 
salicylic acid and initial rapid release of the drug (burst effect) ( 1 ). The o/w 
emulsification process is therefore widely used to encapsulate lipid soluble drugs 
like steroids (I). 
To increase the drug loading of water soluble drugs, an oil-in-oil (o/o) 
emulsification method was developed (1, 10, 26). A water-miscible organic 
solvent like acetonitrile is employed to solubilize the drug in which PLGA or 
PLA are also soluble. This solution is then dispersed into an oil such as light 
mineral oil in presence of an oil soluble surfactant like Span to yield the o/o 
emulsion. Microspheres are finally obtained by evaporation or extraction of the 
organic solvent from the dispersed oil droplets and the oil is washed off by 
solvents liken-hexane. This process is also sometimes referred as water-in-oil 
(w/o) emulsification method (1) . 
A number of formulation and process factors affect microsphere 
formation. The main variables that influence the microencapsulation process and 
the final microsphere product are: (a) the nature and solubility of the drug being 
encapsulated; (b) the polymer concentration, composition. and molecular weight: 
(c) the drug/polymer ratio; (d) the organic solvent used: (e) the concentration and 
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nature of the emulsifier used; (f) the temperature and stirring/agitation speed of 
the emulsification process; and (g) the viscosities and volume ratio of the 
dispersed and continuous phases ( 1, 4, 5, 10). 
(i) Solvents 
Selection of dispersed and continuous phase is important for successful 
microsphere formation and to achieve high drug encapsulation efficiencies. For 
the solvent evaporation/extraction method the dispersed phase selected should be 
immiscible or only slightly miscible with the continuous phase and must have a 
boiling point lower than that of the continuous phase ( 4 ). Bodmeier and 
McGinity have shown that water miscible solvents like acetone and dimethyl 
sulfoxide do not form microspheres upon emulsification (27). Typically, DCM 
and water are used as dispersed and continuous phases respectively. DCM is 
widely used because it is a good solvent for the polymers and due to its high 
volatility it can be easily removed by evaporation. 
A major problem with the use of DCM is its potential toxicity (28). 
Chlorinated solvents in general are considered hazardous to environment and 
undesirable for use in manufacturing processes (28). Chern et al. have reported 
the use of ethyl acetate to prepare PLGA microspheres by the solvent extraction 
process (29). Sah et al. produced microspheres by a two-step extraction process 
using methyl ethyl ketone (MEK) (10 times more soluble than DCM in water) as 
the solvent for PLGA (28, 30). Rapid diffusion of MEK into the extraction 
medium and migration of water into the oil droplets produced hollow 
microspheres having volume mean diameter of 96 µm and 60 to 77% drug 
entrapment (28, 30). The authors concluded that water-immiscibility of the 
dispersed phase is not an absolute requirement for the solvent 
evaporation/extraction process (28, 30). 
For o/o emulsification method, acetonitrile (26, 31-38) is generally used as 
the dispersed phase. Other solvents like acetonitrile/water mixture (24 ). DCM 
(39), N,N-dimethyl formamide (DMF) (40-42) have also been used. The 
continuous phase consists of oils like light mineral oil (26, 33-36, 38, 39), cotton 
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seed oil (24), liquid paraffin (40-42), silicon oil (31), and machine oil (37). When 
prepared by solvent extraction method, heptane has been most commonly used as 
extraction medium (32-38). Thanoo et al. prepared microspheres from PLA using 
DCM, glycerin, and isopropanol/water mixture as the dispersed phase, continuous 
phase, and extraction medium respectively (43) . The same group also reported 
preparation of PGA microspheres using hexafluoroacetone, carbon tetrachloride. 
and dioxan as the dispersed phase, continuous phase, and extraction medium 
respectively ( 43). 
In an article van Hamont et al. have concluded that the particle size of the 
microspheres is a balance of the following two opposite actions: (a) higher 
weights of the external oil phase tend to produce larger diameter microspheres due 
to slowing of the solvent evaporation process and (b) decrease in polymeric 
droplet coalescence due to increase in viscosity of the oil phase tend to decrease 
the diameter of the microspheres (37). 
Sometimes a solvent mixture rather than a solvent alone is employed as 
the dispersed phase (43). Such a solvent mixture consists of a water-immiscible 
solvent such as DCM (44, 45) or chloroform (46, 47) and a water-miscible solvent 
like acetone (44, 46, 47), methanol (45), ethanol (4), or propylene glycol (4). The 
water-miscible solvent provides rapid solvent removal and faster polymer 
precipitation and hardening (44-47). Coombes et al. used DCM-acetone mixture 
in the solvent evaporation process and concluded that solvent removal process is 
rapid and causes entrapment of the stabilizer molecules by physical chain 
entanglement and thus enhancing their stabilizing capacity ( 44). Use of DCM 
alone, however, results in a slow solvent evaporation process, allowing entrapped 
stabilizer molecules to diffuse out into the external aqueous phase with 
consequent loss of their stabilizing capacity ( 44). Thanoo et al. have prepared 
PLGA microspheres using a mixture of two water-immiscible solvents. DCM and 
chloroform by the solvent evaporation process (43). Polard et al. have reported 
that due to poor solubility of morphine in DCM, and good solubility in methanol. 
methanol was used as hydrophilic cosolvent (45). As the fraction of methanol 
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was increased in the DCM/methanol mixture, more morphine dissolved in the 
organic phase and this enhanced the drug entrapment in the microspheres as a 
result of faster precipitation of the polymer (45). However when percentage of 
methanol in the solvent mixture exceeded 60%, the polymer could not be 
dissolved ( 45). Spenlehauer et al. employed DCM:cyclohexane ( 10: 1) mixture 
for producing PLA microspheres (48). Cyclohexane is less volatile than DCM 
and hence evaporation of DCM from the emulsion droplets leads to entrapment of 
cyclohexane in the microspheres, resulting in formation of porous surface 
structures during the final removal of cyclohexane ( 48). 
Sansdrap and Moes have found that the increase in the external aqueous 
phase volume did not affect the final microsphere size while increase in the 
dispersed DCM volume decreased the size with narrow size distribution due to the 
decrease in the viscosity of the internal phase with increasing volume ( 49). 
(ii) Emulsifiers 
During the solvent evaporation/extraction process, there is a gradual 
decrease in the volume and subsequent increase in the viscosity of the dispersed 
oil droplets (4). This affects the droplet size equilibrium and the droplets tend to 
coalesce and produce agglomerates during the early stages of solvent removal ( 1, 
4, 10). This problem could be rectified by adding a small quantity of a droplet 
stabilizer (emulsifier) in the continuous phase ( 1, 4, 10). The emulsifier provides 
a thin protective layer around the oil droplets, and hence reduces their coalescence 
and coagulation (10). As the solvent is removed, the emulsifier continues to 
maintain the spherical shape of the oil droplets and prevents their aggregation, 
until the microspheres are hardened and isolated as discrete particles ( 4 ). 
The physicochemical properties and the concentration of the emulsifier 
strongly influences the microsphere size, shape, and drug encapsulation 
efficiency. The emulsifiers most commonly used in the solvent 
evaporation/extraction process are the hydrophilic polymeric colloids and/or 
anionic or nonionic surfactants ( 4, 10). PV A is by far the most commonly used 
emulsifier (25, 29, 30, 33-35, 45-47, 50-63) in the o/w emulsion method. Others 
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( include poly vinyl pyrrolidone (PVP) (4), alginate (4), gelatin (4), methyl cellulose (MC) (25, 51 , 54, 64, 65), hydroxyalkyl cellulose ( 4, 10), 
Hydroxypropylmethyl cellulose (HPMC) ( 49), polyoxyethylene derivatives of 
sorbitan fatty esters (Tweens) (4, 10), cetyltrimethyl ammonium bromide (4. 10). 
and fatty acid salts like sodium oleate (43 , 66-68). For o/o method, oil soluble 
emulsifiers such as polyoxyethylene fatty ethers (Brijs). Spans. and lecithins have 
been used (1 , 4, 10). 
The appropriate type and concentration of the emulsifier for a particular 
process is apparently commonly determined by trial and error basis, although 
optimization techniques clearly have potential in this area. For most of the 
emulsifiers, the microsphere size decreases with increase in emulsifier 
concentration ( 4, 49). Beyond a certain concentration, the emulsifier is 
ineffective, due to achievement of an optimal packing concentration for the 
emulsion, i.e. condensed monolayer (40). Wakiyama et al. have investigated the 
emulsifying action of sodium alginate in comparison with gelatin and have 
concluded that sodium alginate produced a relatively more viscous aqueous phase 
and hence yielded relatively smaller microspheres as compared to those produced 
by the same amount of gelatin (69). Fong et al. found that when sodium 
hydroxide was added to the aqueous continuous phase, the ionization of the 
emulsifier sodium oleate was increased, which resulted in higher drug 
encapsulation efficiencies and smaller, spherical, but highly porous microspheres 
(70). Jalil and Nixon studied the effects of oil soluble emulsifiers (Spans and 
Brijs) on the size of microspheres prepared by o/o emulsion and concluded that 
more hydrophilic emulsifiers produced smaller microspheres (71 ). Coombs er al. 
prepared PLGA microspheres using various grades of poly(oxyethylene)-
poly(oxypropylene) (PEO-PPO) co-polymers as the surfactants (44). The sol vent 
removal led to entrapment of these surfactant molecules by physical chain 
entanglement and their location at the microsphere surface. The authors stated 
that the PEO-PPO chain length, structure, and conformation influenced the 
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surface coverage of the microspheres, the strength of surfactant attachment, and 
its overall performance (44). 
Some times a combination of emulsifiers have been used to achieve the 
necessary emulsifying action (25, 51 , 72). Cavalier et al. have reported that a 
combination of PVA and MC yielded PLA microspheres having maximum 
sphericity and drug entrapment as compared to formulations that used these 
individual colloids alone (25). This was due to improvement in the rheological 
properties of the combined emulsifiers as compared to their properties when used 
alone. A similar finding was reported by Spenlehauer et al. When the theoretical 
drug loading ranged from 0-30%, 0.25% aqueous PV A solution gave 
microspheres in the size range 25-50µm (51). However, for drug loading in the 
range of 50-60%, 0.25% MC or a PV A:MC (50:50) mixture was necessary to 
produce the microspheres (51). 
(iii) Polymer 
The polymer type, its molecular weight, and the concentration used 
strongly influence the characteristics of the final microspheres. Cavalier et al. 
have reported that a decrease in PLA concentration (increase in drug/PLA ratio) 
resulted in higher drug content in the microspheres (25) . The same group also 
reported slightly higher drug content for PLGA (65:35) microspheres against 
those for PLA microspheres (25). Coombes et al. have reported a decrease in 
polydispersity and particle size of the microparticles as the PLGA concentration 
in it was decreased ( 44 ). In a study, drug content of PLA (molecular weight 
2000) microparticles was higher than PLGA (molecular weights 9000 and 12000) 
and PLA (molecular weight 9000) microparticles due to the rapid rate of polymer 
precipitation at the droplet surface ( 45). The particle size increased from 1.0 ~tm 
for PLGA (RG 505), to 1.1 µm for PLGA (RG 858), to 1.5 mm for PLA (R 208) 
microspheres (73). The drug entrapment was however same for RG 505 and R 
208 (2.8% w/w) while for RG 858 it was slightly higher (3.2% w/w) (73) . In 
another study, microspheres prepared from 16% w/w PLGA had many structural 
defects while those prepared from 5.3% w/w had little structural defects but were 
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aggregated and formed lumps ( 40). Inspite an increase in the PLGA molecular 
weight from 6600 to 19000, microspheres with uniform particle size and no 
structural defects were produced ( 40) . Udupa and Chandrashekar have reported a 
decrease in drug content and increase in microsphere size with increase in 
PLGA/drug ratio. In a peptide adsorption study, Calis et al. found that with 
increase in microsphere concentration (and hence PLGA concentration) the time 
for maximum peptide adsorption decreased (66). Delgado et al. have reported 
that values of certain polymer parameters like polydispersity and degradation 
index (a measure of polymer erosion) are directly related to the weight average 
molecular weight (M,J of the PLA polymer used for microencapsulation (61 ). 
(iv) Drugs 
The biggest disadvantage of the o/w emulsification method is poor 
encapsulation of water soluble drugs ( 1, 4, 10). The o/w emulsification process is 
therefore recommended to encapsulate lipid soluble drugs ( 1 ). Several 
investigators have tried various modifications of the o/w method to minimize 
partitioning and thereby increase the entrapment of water soluble drugs (74 and 
more). Bodmeier and McGinity achieved higher entrapment of ionizable drugs 
like diazepam and quinidine by using high pH external aqueous phase (pH 12), 
where the loss due to ionization of these drugs was reduced (7 4 ). Similarly, 
Wakiyama reported higher drug encapsulation efficiencies for butamben and 
dibucaine when the aqueous phase consisted of 1 % alkali (high pH solution) (69) . 
However tetracaine under similar conditions got ionized and exhibited poor drug 
entrapment ( 69). Po lard et al. used an external phase having a pH of 9 to prevent 
the solubility of morphine in water and thereby reducing its partitioning in the 
external aqueous phase (45) . Contrary to these results, Vaughan et al. have 
reported that increasing the pH of the external aqueous phase to I 0, did not 
increase the loading efficiency of lidocaine (33) . 
The loss of drug can also be minimized by presaturating the aqueous or 
organic phase with the same drug. The drug content of quinidine in PLA 
microspheres increased with increase in quinidine content in the dispersed organic 
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phase (74), while tetracaine entrapment increased with prior saturation of the 
aqueous phase (69). 
Sah et al. have reported that the encapsulation efficiency of PLGA 
microspheres decreased with increasing theoretical loading of the drug 
(progesterone) due to rapid partitioning of the drug in the external aqueous phase 
from the dispersed organic phase (which contained MEK) (30). Polard et al. have 
shown that with increase in drug loading, the drug content of the microspheres 
increased but their encapsulation efficiencies and the microsphere recovery yield 
decreased (45). Also drug entrapment was higher when the drug was present in 
suspension form as compared to when present in the solution form ( 45). A similar 
result was reported by Cavalier et al., where an increase in the drug/polymer ratio 
resulted in increase in the drug content of the microspheres (25) . Thanoo et al. 
have shown an increase in the drug incorporation efficiency and the microsphere 
yield with increase in the theoretical drug loading (43). 
Rosilio et al. have reported that for progesterone loading of 0-30%, the 
microsphere (prepared by o/w method) size was in the range 25-50 µm , and for 
35% loading it increased to 50-75 µm (51). A different observation was made by 
Tsai et al. who prepared microspheres by o/o method (26). Inspite an increase in 
the drug loading from 3.65 to 13.80 %, the microspheres exhibited an average size 
of 95 µm, with a relatively narrow size distribution (26). In another study, an 
increase in nifedipine (a water insoluble drug) loading resulted in subsequent 
increase in its content in the PLGA microspheres but did not influence the mean 
particle size ( 49) . 
Calis et al. carried out peptide adsorption studies and concluded that in 
dilute peptide solutions, peptide-PLGA interaction favored monolayer adsorption 
which fitted the Langmuir adsorption, while at higher peptide concentration. 
peptide-peptide interaction are favored, resulting in multilayer adsorption which 
fitted the Freundlich model (66). In another study, Ouggirala et al. have showed 
that with increased protein loading, the adsorption of protein on PLGA 
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microspheres increased upto a definite value and then remained constant due to 
saturation of the microsphere surface (mono layer coverage) by the protein (75) . 
Bodmeier and McGinity have shown by a Scanning Electron Microscopy 
(SEM) study that for PLGA microspheres, the surface changed from a smooth 
texture at low drug content to a porous honey-comb like structure at higher drug 
loading (74). In another study, PLGA microcapsules containing 8% progesterone 
showed a smooth external morphology while those containing 21 % drug exhibited 
textured and irregularly shaped surface features (30). When the theoretical 
progesterone loading was increased from 10 to 50%, the microsphere surface 
changed from a smooth, uniform appearance to an irregular surface containing 
well-defined progesterone crystals and numerous pores ( 51 ). 
In a study carried out by Benoit et al. , increase in the encapsulated drug 
amount resulted in a gradual decrease in the Tg of PLGA polymer from 48 .3 to 
12.9° C (52). The authors concluded that the drug was molecularly dispersed in 
an amorphous form in PLGA (formation of a stable solution) and thus strongly 
plasticized the polymer (52) . A similar interaction phenomena between the drug 
and PLGA has been reported by Crossan and Whateley (53) and Richey and 
Harris (76). Rosilio et al. have concluded that below 35% loading, progesterone 
is molecularly dispersed in the PLGA glass (51 ). At 35% and above, crystal 
domains of the steroid appeared and two crystalline forms , a and ~ could be 
detected (51). Bodmeier and McGinity (74) and Cavalier et al. (25) have also 
reported similar results of a molecular dispersion of the drug in the polymer glass. 
(v) Process 
Sah et al. prepared microspheres by a two-step extraction-hardening 
process using MEK as a solvent for the PLGA polymer (external aqueous phase 
was presaturated with MEK) (28 , 30). In the first step, the emulsion was 
transferred into 250 ml of aqueous PY A solution where MEK was extracted out 
(30). In the next step the microcapsules were transferred into 500 ml of aqueous 
PY A solution for complete hardening of the microcapsules. The authors 
concluded that the initial extraction rate of MEK were critical for successful 
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microencapsulation (30) . Also, the particle size of the microspheres decreased 
when increasing amount of MEK was predissolved in the external aqueous phase 
before the emulsification process (28). Giordanao et al. used DCM saturated I% 
PV A aqueous phase to make PLGA microspheres (56). Rosilio et al. prepared 
microspheres from PLGA where the solvent (DCM) was removed by an 
interrupted process (51 ). DCM evaporation was interrupted after a definite period 
and the aqueous phase (continuous phase) was completely removed by several 
decantation washings. The DCM evaporation was then continued until the 
microspheres were obtained. This method was developed to minimize formation 
of emulsifier-assisted drug crystals at the microsphere surface and to achieve 
higher drug loading (51 ). Cowsar et al. produced microspheres from PLGA by 
two techniques: solvent extraction-solvent evaporation and solvent evaporation-
solvent extraction ( 4 7). In the former case, most of the acetone was first al lowed 
to diffuse out from the dispersed organic phase (chloroform-acetone mixture) into 
the external aqueous phase, followed by gradual evaporation of the residual 
solvents to give the final microspheres . In the latter case, the o/w emulsion was 
first subjected to solvent (DCM) evaporation for a certain period until semisolid 
droplets were obtained and the residual DCM was removed by the extraction 
process in a large volume of water. Microspheres from evaporation-extraction 
process were less porous and exhibited better encapsulation than those prepared 
from extraction-evaporation process ( 4 7) . 
Vaughan et al. (33 , 34) and Pak et al. (35) have compared the effects of 
the solvent extraction v/s evaporation process on the final microsphere product. 
Microencapsulation of lidocaine base by the evaporation process gave product 
with an yield of 65-80%, volume mean diameter of 120-130 µm, drug content of 
4-10%, smooth and non-porous surface, and only 30-70% loading efficiency (due 
to solubility of lidocaine in the external aqueous phase) (33) . The extraction 
process, however yielded microspheres having lidocaine content in the range of 5-
20%, particle size of 7-10 µm , smooth but very porous particles, and l 00% 
loading efficiencies (33). The authors had used the salt form of the drug 
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(lidocaine hydrochloride), and not lidocaine base for the extraction process (3 3 ). 
Extraction process using lidocaine base resulted in encapsulation efficiency of less 
than l 0% (33). The same group also reported a better product from the extraction 
process for the drug ketoprofen in terms of drug content, loading efficiency, 
particle size, and surface feature as against the evaporation process (34 ). Contrary 
to these results, Pak et al. have reported slightly lower drug contents for PLGA 
microspheres prepared from extraction process as compared to the evaporation 
process (35). 
Some investigators have compared the microspheres produced from the 
o/o method against those produced from the o/w process (24, 39). Wada et al. 
have reported that o/o method gave L-PLA microspheres having smooth spherical 
surface and higher drug entrapment due to reduction in partitioning of drug in the 
external oil phase (24). The o/w process on the other hand gave a poor product 
with drug particles sticking out from the surface and poor drug entrapment (24). 
Contrary to these results, Menegatti et al. have stated that the o/w process 
produced microspheres having average size of 38.4 µm with no aggregation, as 
compared to the o/o method which yielded a poor product having severe 
aggregation (39). 
The rate of temperature rise and the operating temperature for solvent 
evaporation strongly influences the microsphere product. Kyo et al. have reported 
that the solvent evaporation at the rate of 0.5 and 2.0° C/min in an o/o process 
yielded PLGA microspheres having many structural defects as against 
evaporation at 0.2° C/min which produced fewer defects (40). Wakiyama et al. 
have found that the organic solvent removal by heating at 40° C produced a 
viscous aqueous phase and resulted in relatively larger microcapsules, than those 
produced by removing solvent by vacuum at room temperature without any heat 
(69) . Tice and Gilley have pointed out that very rapid DCM evaporation would 
cause DCM to boil of from the emulsion droplets, yielding microspheres with 
cracks and pin-holes (76). Jalil and Nixon have stated that when temperature of 
85° C were used (above the boiling point of the solvent acetonitrile), highly 
27 
( 
porous microspheres, having internal honey-comb like structure were produced 
(77). Van Hamont et al. found a predictable linear increase in the average PLGA 
microsphere size as the temperature of the continuous oil phase (various grades of 
machine oil) was increased from 20 to 30° C during the evaporation (of 
acetonitrile) phase of the o/o emulsification process (37). This linearity was lost 
as the temperature was increased from 30 to 40° C due to changes in the solubility 
of acetonitrile in oil (3 7). By heating an o/w emulsion for 2 hr at 50° C, Vaughan 
et al. could increase the drug loading efficiency from 20-30% to 75-85% (34). 
Evaluation of hydrocortisone stability in PLA microspheres at different 
temperature/time storage conditions revealed no drug degradation (25). 
Generally, increasing the stirring rate decreases the microsphere size and 
narrows the size distribution (49). Crossan and Whateley prepared PLGA 
microspheres in the size range of 40-60 µm by using an overhead paddle stirrer 
and stirring for four hours at room temperature (53). Modification of this system 
by addition of a baffle reduced their size to 20-40 µm (53) . A similar result was 
reported by Bodmeier and McGinity (78). The side baffles reduced the effective 
diameter of the vessel and hence lead to formation of smaller emulsion droplets. 
Also, the baffles reduced the turbulence in the suspension mixture, thereby 
increasing the stability of droplet suspension and the product yield. Further size 
reduction (5-10 µm) was achieved by first high speed stirring ( 1500 rpm) for 10 
min using a Silverson homogenizer, followed by magnetic stirring for 18 hr. to 
enable complete evaporation of DCM (53). Rosilio et al. found out that for a drug 
loading of 0-30%, a stirring speed of 480 rpm was required and for a drug loading 
of 50-65%, stirring speed of 645 rpm was necessary to produce the microspheres 
(51 ). Coombes et al. have stated that, increasing the stirring rate of emulsion 
resulted in decrease in polydispersity of the PLGA microspheres but not in their 
particle size (44). 
(2) Double (multiple) emulsion process 
The double emulsion process is essentially an water-in-oil-in-water 
(w/o/w) method and is best suited to encapsulated water-soluble drugs like 
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peptides, proteins, and vaccines, unlike the o/w method which is ideal for water-
insoluble drugs like steroids ( 1, 4, 5). A buffered or plain aqueous solution of the 
drug (sometimes containing a viscosity building and/or stabilizing protein like 
gelatin) is added to an organic phase consisting of PLGA and/or PLA solution in 
DCM with vigorous stirring to form the first microfine w/o emulsion. This 
emulsion is added gently with stirring into a large volume water containing an 
emulsifier like PV A to form the w/o/w emulsion. The emulsion is than subjected 
to solvent removal by either evaporation or extraction process. In the former case 
the emulsion is maintained at reduced pressure or at atmospheric pressure and 
stirred to enable DCM to evaporate. In the latter case the emulsion is transferred 
to a large quantity of water (with or without surfactant) with stirring, into which 
DCM is diffused out. The solid microspheres so obtained are then washed and 
collected by filtration, sieving, or centrifugation. These are then dried under 
appropriate conditions or are lyophilized to give the final free flowing 
microsphere product. 
Some groups have reported using ethyl acetate as the polymer solvent and 
hydrophilic stabilizers like Pluronic F68, PEG 4600, BSA, HSA or sodium 
glutamate for protein/peptide drugs (79). Singh et al. used a blend of PY A and 
PVP in the outer aqueous phase to make PLA/PLGA microspheres (80). Cohen et 
al. have used an outer aqueous PVA phase saturated with DCM to prepare PLGA 
microspheres (81 ). Al par et al. have reported preparation of PLA microspheres in 
which the inner aqueous phase contained MC besides PVA or PVP (82, 83). 
They found that particles containing PVP were more hydrophobic, exhibited 
higher drug loading and encapsulation efficiency, and showed decreased burst 
effect as compared to those containing PV A (82, 83). The addition of a 
stabilizing polymer (BSA), reduced the net encapsulation efficiency of the protein 
drug (82). 
A number of hydrophilic drugs like the peptide leuprolide acetate. a 
luteinizing hormone-releasing hormone (LH-RH) agonist (84-89), vaccines (2 1. 
79-81 , 83, 90-124 ), proteins/peptides ( 82, 125-138), and conventional molecules 
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(139-151) have been successfully encapsulated by this method. Various 
formulation and process variables significantly affect the final microsphere 
product and the drug release from them. 
(i) The primary w/o emulsion 
Ogawa et al. have concluded that the encapsulation efficiency of the drug 
in PLA and PLGA microparticles increased with the increase in viscosity of the 
inner aqueous phase (containing gelatin) and also by increasing the viscosity of 
the whole w/o emulsion (by decreasing the amount of DCM) (84 ). The authors 
concluded that the high viscosity prevented the migration of the inner aqueous 
phase to the outer water phase due to local demulsification produced by the 
vigorous stirring (84). Similar results have been reported by Jeffery et al. who 
also found an increase in the microparticle size with the increase in viscosity of 
the inner aqueous phase (92). However increasing the viscosity of the inner 
aqueous phase by adding PY A had no effect on the drug entrapment or the 
particle size of the final microparticles (92). Jeffery et al. and others have 
reported that an increase in particle size and drug entrapment was observed 
following an increase in the internal aqueous phase volume (92, 118). In a study, 
Crotts and Park have stated that the volume of the inner aqueous phase drastically 
affected the morphology of the final microspheres and the subsequent drug release 
from them; those prepared from 5.6% aqueous phase fraction were dense and non-
porous while those prepared from 22. 7% aqueous phase fraction were porous in 
nature (118). Alonso et al. have reported that incorporation of a lipophilic 
surfactant, L-a-phosphatidylcholine (by dissolving it in chloroform and adding 
this solution to the DCM phase) produced more hydrophobic microspheres, 
causing reduction of the microsphere size and increase in particle porosity due to 
better stabilization of the inner w/o emulsion (100) . Other researchers have also 
reported use of L-a-phosphatidylcholine ( 112). In another study it was found that 
a decrease in the DCM phase volume yielded particles with dense core (81 ). 
The entrapment efficiency of the drug increased with decrease in drug 
loading and increase in particle size (84) . However other groups have found no 
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relationship between encapsulation efficiency and drug loading (92. I 04 ). Jeffery 
et al. have reported that an increase in the antigen/PLGA ratio resulted in increase 
in drug entrapment by PLGA and a small increase in the mean particle size of the 
final microparticles (92). Also an SEM analysis revealed that at low 
antigen/PLGA smooth particles were produced but at higher ratios the particles 
were pitted and some particles had collapsed (92). The authors attributed this to 
high surface concentration of antigen which became soluble in the surrounding 
external phase, leaving a pitted surface and in some cases this caused the 
microparticles to collapse (92). In another study small particles were produced 
when the volume ratio of DCM to PLA was low (84). 
Jeffery et al. have reported the effect of hydrophobicity (molecular weight) 
of the polymer on the entrapment of the antigen; more hydrophobic (high 
molecular weight of 53K) PLGA, showed relatively lower entrapment levels of 
the drug than less hydrophobic 22K PLGA (92). However, Alonso et al. found no 
relationship in the encapsulation efficiency with respect to polymer composition 
(PLA v/s PLGA) and molecular weight (3K v/s 1 OOK) (79). Okada et al. have 
reported that an increase in the content of water-soluble oligomers (free acid 
content) in PLA resulted in increase in the burst release of the encapsulated drug 
(87) . Also increase in the Tg of the PLA and PLGA microspheres was observed 
with increase in drug loading (87). Alonso et al. have pointed out an increase in 
the microparticle size with increase in the molecular weight and the concentration 
of the polymer (79, 100). In a study, Benoit et al. found that microparticles 
prepared from PLGA were relatively larger and exhibited higher drug entrapment 
efficiency as compared to those prepared from PCL (124). Hilbert et al. used an 
aqueous liposoma°I suspension as the inner aqueous phase and prepared 
microencapsulated liposomes (109). These showed an higher burst effect as 
compared to the normal microspheres due to amphiphilic nature of the 
phospholipids which generated porous matrix surface ( 109). Sah et al. have 
reported that microcapsules containing PLA5000 (molecular weight 5000) or 
PLGA5000 (molecular weight 5000) into PLGA 75:25 microcapsules exhibited 
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increased degradation rates as compared to those containing PLGA 75:25 alone 
(117, 119, 120). The authors found that PLA5000 plasticized PLGA 75:25 and 
facilitated its faster degradation (120). Other groups have also reported the effect 
of PLGAs having different molecular weight and lactide/glycolide ratio on the 
final microparticle size, drug entrapment, and the degradation rate of the polymer 
(94, 106). 
Microparticles loaded with greater amount of drug, gave a greater burst 
release of the drug due to increase in the number of channels formed by the 
hydrophilic drug (84, 87, 120). In a study, Alonso et al. have reported that the 
microparticles prepared by the double emulsion method (drug dissolved in the 
inner aqueous phase) produced more regular microspheres with better control over 
drug release, than those prepared by powder dispersion method (drug powder 
dispersed in DCM phase) (100). Reich has noted that the encapsulated protein 
drugs decrease the interfacial tension between the inner aqueous phase and the 
DCM phase of the o/w emulsion (123). The properties of the protein drug has a 
substantial effect on its entrapment and release thus leading to a different 
optimum for different protein/polymer combinations ( 123 ). 
Cohen et al. have reported that for microspheres in which the inner 
emulsion was prepared using low shear (e.g. vortex mixing), the particles were 
large in size and the drug encapsulation was low as compared to microspheres in 
which the inner emulsion was prepared using high shear (e.g. probe sonication) 
which yielded smaller particles with higher encapsulation efficiency (81 ). 
However Sah et al. reported no effect of the shear rate (to prepare the o/w 
emulsion) on the encapsulation efficiency and the final particle size of 
PLA/PLGA microcapsules; particles prepared from low shear rate were however 
more porous than those prepared from high shear rate (116). 
(ii) The double w/o/w emulsion 
In a study Ogawa et al. have reported that smaller microparticles were 
produced when the mixing speed during emulsification of the w/o emulsion into 
the double w/o/w emulsion was increased (84). A similar result was reported by 
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Uchida and Goto, who also found a decrease in the drug loading efficiency with 
increase in the stirring rate (105). Also an increase in the external phase volume 
led to a decrease in the particle size of the micro particles (84). Jeffery et al. have 
reported an increase in the drug entrapment and the particle size with increase in 
the external aqueous phase volume (92). 
Jeffery et al. found a reduction in particle size as the concentration of PY A 
increased in the external aqueous phase; the entrapment of the drug was however 
not affected (92). The authors attributed this to unstable emulsion droplets at low 
PY A concentration resulting in formation of larger microparticles as compared to 
those prepared from high PV A concentration (92). Singh et al. investigated the 
residual PY A content in PLGA microparticles and concluded that various process 
parameters like volume and concentration of the aqueous PY A solution and the 
number of washes in the microencapsulation process could control the residual 
levels of PV A within the acceptable limits (99). 
Alonso et al. have compared microsphere preparation by two methods in 
which the final organic solvent (DCM) was removed by evaporation and by 
extraction into 2% aqueous isopropanol solution; no major difference was found 
in the physical characteristics and the controlled drug release properties of the 
resultant microspheres. The extraction technique however, yielded the 
microspheres in only 30 min (79, 100). Other groups have also reported use of 
2% aqueous isopropanol solution to remove the solvent ( 113). 
(iii) Drugs 
Researchers at Takeda Chemical Industries have reported successful 
encapsulation of leuprolide acetate, a luteinizing hormone-releasing hormone 
(LH-RH) agonist (for treating endometriosis) into PLGA microparticles by the 
double emulsion method (84-89). A pseudo-zero order release profile (for 1 
month) after administering PLGA loaded leuprolide acetate in rats through s.c. 
and i.m. routes (85 , 86, 88) and a three-month release profile following a s.c. 
injection (87) has been reported by these researchers. 
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There is a lot of interest in delivering vaccines through PLA/PLGA 
microparticles and immense literature has been published on this aspect (13. 16, 
28,30,32-36,38,40,41,54,55,64,65, 74, 100, 102, 106-109, 114. 142. 155). A 
number of vaccines/immunogenic agents like ovalbumin (30, 32-36, 42, 64, 65. 
155, 160), Dermatophagoides Pteronysinuss for hyposensitization therapy (3 8. 
40), cholera toxin (41), tetanus toxoid (79, 100, 106, 114). ricin toxoid (102). HIV 
vaccine (102), birth control vaccine (107, 109), BSA (39, 54, 55 , 81, 95. 124. 139. 
140-143, 149, 151, 160), influenza toxin (28), rotovirus (13). adenovirus (16). 
lysozyme (39), and Schistosoma mansomi against Schistosomiasis (93) have been 
successfully delivered by encapsulation into PLA/PLGA microparticles. These 
have been delivered by s.c., i.m., and oral route to provide pulse as well as 
sustained immune response for days, weeks, and months. 
Besides vaccines, other peptide/protein based drugs and certain synthetic 
drugs have also been successfully loaded into PLA/PLGA microparticles by the 
double emulsion method and administered for prolonged release effect (82, 125-
151 ). 
B. Phase Separation (Coacervation) 
The coacervation method consists of decreasing the solubility of the 
encapsulating polymer by addition of a third component to the polymer solution 
in an organic solution (1, 4, 5). At a particular point, the process yields two liquid 
phases (phase separation): the polymer containing coacervate phase and the 
supernatant phase depleted in polymer. The drug which is dispersed/dissolved in 
the polymer solution is coated by the coacervate. Thus the coacervation process 
includes the following three steps: (i) phase separation of the coating polymer 
solution, (ii) adsorption of the coacervate around the drug particles, and (iii) 
solidification of the microspheres ( 152). 
First, the polymer is dissolved in an organic solution. The water-soluble 
drugs like peptides and proteins are dissolved in water and dispersed in the 
polymer solution (w/o emulsion). Hydrophobic drugs like steroids are either 
solubilized or dispersed in the polymer solution. An organic nonsolvent is then 
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added to the polymer-drug-solvent system with stirring which gradually extracts 
the polymer solvent. As a result the polymer is subjected to phase separation and 
it forms very soft coacervate droplets (size controlled by stirring) which entrap the 
drug. This system is then transferred to a large quantity of another organic 
nonsolvent to harden the microdroplets and form the final microspheres which are 
collected by washing, sieving, filtration, or centrifugation, and are finally dried ( 4, 
152). 
The phase separation method, unlike the o/w emulsification method is 
suitable to encapsulate both. water-soluble as well as water-insoluble drugs. since 
its a non-aqueous method. However the coacervation process is mainly used to 
encapsulate water soluble drugs like peptides, proteins, and vaccines. The 
addition rate of first nonsolvent should be such that the polymer solvent is 
extracted slowly, so that the polymer has sufficient time to deposit and coat 
evenly on the drug particle surface during the coacervation process (4) . The 
concentration of the polymer used is important as well, since too higher 
concentrations would result in rapid phase separation and nonuniform coating of 
the polymer on the drug particles. Due to absence of any emulsion stabilizer in 
the coacervation process, agglomeration is a frequent problem in this method ( 4 ). 
The coacervate droplets are extremely sticky and adhere to each other before the 
complete phase separation or the hardening stages of this method. Adjusting the 
stirring rate, temperature, or the addition of an additive is known to rectify this 
problem (4). 
Unlike the solvent evaporation/extraction process, the requirement of 
solvents for the polymer are less stringent since the solvent need not be 
immiscible with water and the boiling point can be higher than that of water ( 4 ). 
DCM, acetonitrile, ethyl acetate, and toluene have been used in this process ( 152-
163). The nonsolvents affect both the phase separation and the hardening stages 
of the coacervation process. The nonsolvents should not dissolve the polymer or 
the drug and should be miscible with the polymer solvent (152-160). The second 
nonsolvent should be relatively volatile and should easily remove the first viscous 
35 
( 
nonsolvent by washing. Some of the oils used as the first nonsolvent are silicone 
oil, vegetable oils, light liquid paraffin, low molecular weight liquid 
polybutadiene, and low molecular weight liquid methacrylic polymers ( 4, 152-
163). Examples of the second nonsolvent include aliphatic hydrocarbons like 
hexane, heptane, and petroleum ether ( 4, 152-163 ). 
In the coacervation process the phase equilibrium is never reached and 
hence the system is constantly out of equilibrium ( 4) . Therefore the formulation 
and process variables significantly affect the kinetics of the entire process and 
ultimately the characteristics of the final microspheres. In a classic article, Nihant 
et al. have investigated the effect of several process factors on the coacervation 
process (152). With increase in the aqueous phase/organic phase volume ratio 
from 0.02 to 0.12% w/w the 'stability window' (an area in the phase diagram 
where the dispersed aqueous phase is efficiently coated by the coacervate) was 
unmodified and only got slightly narrower ( 152). An SEM picture revealed that 
the morphology of the particles changed from a spherical shape for 0.02 ratio to a 
deformed one at higher ratio of 0.12. Above water contents of 0.12. the 
microspheres became brittle and spontaneously released the encapsulated drug 
solution during filtration ( 152). With decrease in the stirring rate from 800 to 400 
rpm for the aqueous drug dispersion in PLGAIDCM solution, the particle size 
increased from 40.0 to 51.5 µm and for 300 rpm no microparticles were formed 
(152). Similarly with decrease in the stirring rate from 200 to 130 rpm for the 
phase separation by adding silicone oil, the particle size increased from 40.0 to 
58.0 µm and for 100 rpm no microparticles were formed. For the addition rate (of 
silicone oil) of 18 ml/min microparticles of the size 40.0 ~Lm were formed and 
their size decreased to 39.1 µm when the addition rate was decreased to 5. 7 
ml/min (152). However, with further decrease in the addition rate to 0.65 ml/min, 
the particle size increased to 53.1 µm and aggregates were formed and in certain 
cases no microparticles were formed. The authors concluded that 
microencapsulation by coacervation is a complex process that depends on the 
interplay of several kinetic parameters ( 152). In another paper, the same group 
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has reported the effects of weight, volume, composition, and viscosity of the 
coacervate and supernatant phases on the size distribution, surface morphology, 
and internal porosity of the final microparticles ( 162). 
Other groups have also reported microencapsulation by coacervation ( 153-
161, 163). Vidmar et al. induced phase separation of a drug-PLA-DCM 
suspension by addition of n-heptane to give particles in the range of 50-500 ~Lm 
and in another study they used chloroform instead of DCM to dissolve the 
polymer (1 ). Nakano et al. used an ethyl acetate solution of PLA/carboxymethyl 
ethyl cellulose blend and suspended the drug particles in it prior to inducing phase 
separation by adding ethyl ether to finally give smooth microspheres having mean 
size of 16.4 µm (1 ). Fong et al. carried out microencapsulation at low 
temperature, where the drug was suspended in PLA/toluene solution at -65° C and 
phase separation was induced by dropwise addition of isopropanol with constant 
stirring to yield microspheres in the range of25-50 µm (164). Manda! et al. 
added the suspension of water soluble diltiazem or metoprolol in PLGA/DCM 
solution to a silicone oil:DCM solution (1 :6 ratio) with stirring and the 
coacervates obtained were hardened by petroleum ether to yield microspheres 
with high encapsulation efficiencies (153). In an article, Ruiz et al. have 
concluded that the polymer properties such as hydrophobicity or chain length, 
viscosity of the silicone oil used, the concentration of the polymer, and the 
polymer solvent/silicone oil ratio greatly affected the overall coacervation process 
and thereby the characteristics of the final microsphere product ( 165). 
Leelarasamee et al. have reported preparation of PLA microcapsules by solvent 
partitioning to achieve phase separation ( 159). A solution of hydrocortisone and 
PLA in DCM was slowly injected into a mineral oil stream with a constant 
injection rate and needle size. As DCM partitioned into the mineral oil phase. the 
polymer precipitated and encapsulated the drug. The microcapsules were finally 
washed with hexane and they had a size of250 µm with 90% yield (159). 
C. Spray Drying 
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Injectable biodegradable PLA and PLGA microparticles have been 
successfully prepared by double emulsion and phase separation as discussed in the 
previous sections. The coacervation method tends to produce particles which are 
agglomerated, there is difficulty in mass production, the method requires large 
quantities of organic solvent, and it is difficult to remove residual solvents from 
the final microsphere product ( 166). The double emulsion method, on the other 
hand, requires many steps, rigid control of the temperature and viscosity of the 
inner w/o emulsion, and is difficult to encapsulate higher concentration of 
hydrophilic drugs (1 , 166). Contrary to these methods, the spray drying method is 
very rapid, convenient, easy to scale-up, involves mild conditions, and is less 
dependent on the solubility parameter of the drug and the polymer ( 1, 166, 167). 
Wise et al. reported the preparation of PLGA microcapsules in which. a 
solution of PLGA, hexafluro-2-propanol, benzene, and the drug was sprayed to 
produce particles ofless than 125 µm (168). Bodmeier and Chen prepared 
microspheres by spray drying where a water soluble drug (theophylline) was 
suspended or a water-insoluble drug (progesterone) was dissolved in a PLA/DCM 
solution and then spray dried to produce particles of less than 5 µm ( 169). Due to 
incompatibility of the hydrophilic drug and PLA, needle shaped crystals grew on 
the microsphere surface, while the progesterone-PLA solution gave smooth 
particles. The nature of the solvent used, temperature of the solvent evaporation, 
and presence of PLA microspheres during the spray drying process affected the 
polymorphic form of progesterone. A major problem encountered with this 
technique was the formation of fibers due to insufficient force available to 
breakup the polymer solution. An efficient dispersion of the filament into 
polymer droplets was dependent on the type of polymer and the viscosity of the 
spray solution. Other groups have also reported successful preparation of PLGA 
and PLA particles using the spray drying technique (167, 170-174). 
Wagenaar and Muller spray dried a solution of the polymer, DCM. and the 
drug piroxicam to yield microspheres which were hollow (no solid core) ( 167). 
DL-PLA microparticles were more spherical and smooth than those made from 
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Figure I-Schematic representation of the novel modified microencapsulation 
process to produce various injectable biodegradable PLGA devices 
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( Figure 2a-Optical micrograph of the in situ formed PLGA implant 
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( Figure 2b-Optical micrograph of the in situ formed microspheres 
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Figure 2c-Optical micrograph of the isolated microspheres 
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Table I-Percentage cytochrome c encapsulation efficiency and particle size studies 
of the various injectable biodegradable PLGA devices 
Injectable biodegradable Percentage cytochrome c Particle size (µm) 
PLGA device encapsulation efficiency 
Jn situ formed implant 52.8 
-
In situ formed 74.5 98 .6 
microspheres 
Isolated microspheres 90.3 84.3 
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( Figure 3-In vitro cytochrome c release from various injectable biodegradable 
PLGA devices 
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CONCLUSION AND FINAL REMARKS 
The salient features of the novel microencapsulation process and the drug 
delivery sytem described in this .research project are as follows: 
(1) The sytem excluded the use of unacceptable organic solvents like 
methylene chloride and used acceptable vehicle mixture instead to prepare 
biodegradable PLGA microspheres. 
(2) The sytem formed drug containing PLGA microglobules 
("premicrospheres" or "embryonic microspheres") which could be 
considered as precursors to the final microsphere product: these on coming 
in contact with water hardened to form discreet PLGA microspheres (in 
situ formed microspheres) which subsequently exhibited non-variable. 
predictable, and controlled drug release profile. 
(3) Unlike the traditional methods, this system precluded the need for 
reconstitution of the PLGA microspheres as they are formed in situ. 
( 4) Various formulation varibles affected the characteristics of this system. 
(5) The formulation and process conditions did not adversely affect the 
physical stability of the encapsulated protein drugs. 
(6) Besides in situ forming microspheres, the novel microencapsulation 
method can be modified to produce in situ formed implant or isolated 
microspheres; these drug loaded devices exhibited different characteristics. 
(7) This research project makes a significant overall contribution to the 
knowledge of the underlying theoretical principles of drug delivery 
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through biodegradable devices and in particular, problems associated with 
protein drug delivery. 
(8) The novel nature of the system provides a high probability that a patent 
application would be filed. 
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